The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1.

In this multi-center study of 50 patients with advanced non-small cell lung cancer testing positive for ROS1 gene rearrangement, the response rate was 72 percent, with 3 complete responses and 33 partial responses. Median progression-free survival – the time it takes for the disease to resume its growth after being slowed by treatment – is estimated at 19.2 months with exactly half of patients remaining on observation for disease progression that has not yet occurred.

READ FULL ARTICLE Curated publisher From Medical News Today